MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
